Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.2.1.17 (lysozyme)
 21,489 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Amyloidosis of the gastrointestinal tract, with biopsy-proven disease, is rare. We reviewed a series of patients who presented with biopsy-proven gastrointestinal amyloidosis and report their clinical characteristics, treatments, and survival. This is a retrospective review of data prospectively collected from January 1998 to December 2011 in a tertiary referral center; 2,334 patients with all types of amyloidosis were evaluated during this period. Seventy-six patients (3.2%) had biopsy-proven amyloid involvement of the gastrointestinal tract. Their median age was 61 years (range, 34-79). Systemic amyloidosis with dominant gastrointestinal involvement was present in 60 (79%) patients, whereas the other 16 (21%) patients had amyloidosis localized to the gastrointestinal tract without evidence of an associated plasma cell dyscrasia or other organ involvement. Of the 60 systemic cases, 50 (83%) had immunoglobulin light-chain, five (8%) had familial lysozyme, three (5%) had wild-type transthyretin, and two (3%) had mutant transthyretin amyloidosis. The most frequent symptoms for all patients were weight loss in 33 (45%) and gastrointestinal bleeding in 27 (36%). Incidental identification of amyloidosis on routine endoscopic surveillance played a role in the diagnosis of seven patients with systemic immunoglobulin light-chain, and four patients with immunoglobulin light-chain localized to the gastrointestinal tract. Amyloid protein subtyping was performed in 12 of the cases of localized disease, and all had lambda light chain disease. Of the 50 patients with systemic immunoglobulin light-chain amyloidosis, 45 were treated with anti-plasma cell therapy. The median survival has not been reached for this group. For the 16 patients with localized gastrointestinal amyloidosis, supportive care was the mainstay of treatment; none received anti-plasma cell therapy. All 16 are alive at a median follow-up of 36 months (range, 1-143). Patients with biopsy-proven gastrointestinal amyloidosis often present with weight loss and bleeding. In localized cases, all that underwent typing were due to lambda light chain amyloidosis and none progressed to systemic disease during the period of follow-up. Most patients with systemic disease had immunoglobulin light-chain, and their tolerance of therapy and median survival were excellent. Although a rare manifestation of amyloidosis, staining for amyloid should be considered in patients undergoing gastrointestinal biopsy who have unexplained chronic gastrointestinal symptoms.
 ...
PMID:Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. 2273 17

Systemic amyloidosis is a hereditary disorder that mostly arises as a result of specific point mutations to the wild type gene of lysozyme, forming mutant lysozyme variants leading to aggregation of the protein. The small monomeric protein Hen Egg White Lysozyme (HEWL) is a structural homolog of Human Lysozyme and is widely used as a model protein to investigate protein aggregation. In the present study, we have investigated the effect of 1-methylisatin, an indole derivative and glyoxal, a reactive dicarbonyl compound, on stress-induced aggregation of HEWL. Interaction of the compounds with HEWL induced changes in structure and surface hydrophobicity of the protein as evident from CD spectroscopy, tryptophan fluorescence and ANS binding studies. Additional experiments (Thioflavin T fluorescence, AFM imaging and DLS studies) demonstrate that stress induces amyloid-like fibrillation of HEWL, however, prior modification of the protein with glyoxal or 1-methylisatin significantly reduces its susceptibility to aggregation. High resolution mass spectrometric analysis indicated that 1-methylisatin primarily complexes with the protein in the form of a dimer. On the other hand, glyoxal-mediated modification of the protein induces formation of glycated adducts (carboxymethyllysine, hydroimidazolone). The results highlight possible clinical implications of the compounds in treatment of systemic amyloidosis and protein conformational disorder.
 ...
PMID:Effect of glyoxal and 1-methylisatin on stress-induced fibrillation of Hen Egg White Lysozyme: Insight into the anti-amyloidogenic property of the compounds with possible therapeutic implications. 3306 56